To examine whether the reduced incidence of preeclampsia in non-diabetic obese pregnant women treated with metformin is mediated by changes in insulin resistance.
Methods
This was a secondary analysis of obese pregnant women in a randomised trial (MOP trial). Fasting plasma glucose and insulin were measured in 384 of the 400 women who participated in the MOP trial. Homeostasis model assessment of insulin resistance (HOMA-IR) was compared in the metformin and placebo groups and in those that developed preeclampsia versus those that did not develop preeclampsia.
Results
At 28 weeks, median HOMA-IR was significantly lower in the metformin group. Logistic regression analysis demonstrated that there was a significant contribution in the prediction of preeclampsia from maternal history of chronic hypertension and gestational weight gain, but not HOMA-IR either at randomisation (p = 0.514) or at 28 weeks (p = 0.643).
Conclusions
Reduced incidence of preeclampsia in non-diabetic obese pregnant women treated with metformin is unlikely to be due to changes in insulin resistance.
SebireNJJollyMHarrisJPet al.Maternal obesity and pregnancy outcome: A study of 287, 213 pregnancies in London. Int J Obes Relat Metab Disord2001; 25: 1175–1182.
2.
SyngelakiABredakiFEVaikousiEet al.Body mass index at 11–13 weeks’ gestation and pregnancy complications. Fetal Diagn Ther2011; 30: 250–265.
3.
O’BrienTERayJGChanW-S. Maternal body mass index and the risk of preeclampsia: A systematic overview. Epidemiology2003; 14: 368–374.
4.
SyngelakiANicolaidesKHBalaniJet al.Metformin versus placebo in obese pregnant women without diabetes mellitus. N Engl J Med2016; 374: 434–443.
5.
WallaceTMLevyJCMatthewsDR. Use and abuse of HOMA modeling. Diabetes Care2004; 27: 1487–1495.
6.
KirwanJPHuston-PresleyLKalhanSCet al.Clinically useful estimates of insulin sensitivity during pregnancy: Validation studies in women with normal glucose tolerance and gestational diabetes mellitus. Diabetes Care2001; 24: 1602–1607.
7.
D’AnnaRBavieraGCorradoFet al.Adiponectin and insulin resistance in early- and late-onset pre-eclampsia. BJOG2006; 113: 1264–1269.
8.
Cemgil ArikanDOzkayaMAdaliEet al.Plasma lipocalin-2 levels in pregnant women with pre-eclampsia, and their relation with severity of disease. J Matern Fetal Neonatal Med2011; 24: 291–296.
9.
AbhariFRGhanbari AndariehMFarokhfarAet al.Estimating rate of insulin resistance in patients with preeclampsia using HOMA-IR index and comparison with nonpreeclampsia pregnant women. Biomed Res Int2014; 2014: 140851–140851.
10.
GarcesMFPeraltaJJRuiz-LinaresCEet al.Irisin levels during pregnancy and changes associated with the development of preeclampsia. J Clin Endocrinol Metab2014; 99: 2113–2119.
11.
LiuHWuJWangHet al.Association of serum omentin-1 concentrations with the presence and severity of preeclampsia. Ann Clin Biochem2015; 52: 245–250.
12.
CetinOKurdogluZKurdogluMet al.Chemerin level in pregnancies complicated by preeclampsia and its relation with disease severity and neonatal outcomes. J Obstet Gynaecol2017; 37: 195–199.
13.
Romero-GutierrezGMalacaraJMAmadorNet al.Homeostatic model assessment and risk for hypertension during pregnancy: A longitudinal prospective study. Am J Perinatol2004; 21: 455–462.
14.
SalamalekisEVitoratosNMakrakisEet al.No association between insulin resistance and preeclampsia. J Matern Fetal Neonatal Med2005; 18: 113–115.
15.
HaugenFRanheimTHarsemNKet al.Increased plasma levels of adipokines in preeclampsia: Relationship to placenta and adipose tissue gene expression. Am J Physiol Endocrinol Metab2006; 290: E326–333.
16.
FasshauerMWaldeyerTSeegerJet al.Serum levels of the adipokine visfatin are increased in pre-eclampsia. Clin Endocrinol (Oxf)2008; 69: 69–73.
17.
NegratoCAJovanovicLTambasciaMAet al.Association between insulin resistance, glucose intolerance, and hypertension in pregnancy. Metab Syndr Relat Disord2009; 7: 53–59.
18.
ValerioEGMullerALLMartins-CostaSHet al.Are insulin resistance index, IGF-1 and metabolic syndrome components correlates with severe preeclampsia?Hypertens Pregnancy2011; 30: 302–310.
19.
CanMMCanEOzverenOet al.Epicardial fat tissue thickness in preeclamptic and normal pregnancies. ISRN Obstet Gynecol2012; 2012: 389539–389539.
20.
RobertsJMRedmanCW. Pre-eclampsia: more than pregnancy-induced hypertension. Lancet1993; 341: 1447–1451.
21.
GrangerJPAlexanderBTLlinasMTet al.Pathophysiology of hypertension during preeclampsia linking placental ischemia with endothelial dysfunction. Hypertens2001; 38: 718–722.
22.
MaynardSEMinJ-YMerchanJet al.Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest2003; 111: 649–658.
23.
NagamatsuTFujiiTKusumiMet al.Cytotrophoblasts up-regulate soluble fms-like tyrosine kinase-1 expression under reduced oxygen: An implication for the placental vascular development and the pathophysiology of preeclampsia. Endocrinology2004; 145: 4838–4845.
24.
VenkateshaSToporsianMLamCet al.Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med2006; 12: 642–649.
25.
PoweCELevineRJKarumanchiSA. Preeclampsia, a disease of the maternal endothelium: The role of antiangiogenic factors and implications for later cardiovascular disease. Circulation2011; 123: 2856–2869.
26.
BrownfootFCHastieRHannanNJet al.Metformin as a prevention and treatment for preeclampsia: Effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction. Am J Obstet Gynecol2016; 214: 356.e1–356.e15.
27.
ViolletBGuigasBSanz GarciaNet al.Cellular and molecular mechanisms of metformin: An overview. Clin Sci (Lond)2012; 122: 253–270.
28.
GlueckCJGoldenbergNWangPet al.Metformin during pregnancy reduces insulin, insulin resistance, insulin secretion, weight, testosterone and development of gestational diabetes: Prospective longitudinal assessment of women with polycystic ovary syndrome from preconception throughout preg. Hum Reprod2004; 19: 510–521.
29.
KnowlerWCBarrett-ConnorEFowlerSEet al.Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med2002; 346: 393–403.
30.
BegumMRKhanamNNQuadirEet al.Prevention of gestational diabetes mellitus by continuing metformin therapy throughout pregnancy in women with polycystic ovary syndrome. J Obstet Gynaecol Res2009; 35: 282–286.
31.
KhattabSMohsenIAAboul FoutouhIet al.Can metformin reduce the incidence of gestational diabetes mellitus in pregnant women with polycystic ovary syndrome? Prospective cohort study. Gynecol Endocrinol2011; 27: 789–793.
32.
KumarPKhanK. Effects of metformin use in pregnant patients with polycystic ovary syndrome. J Hum Reprod Sci2012; 5: 166–169.
33.
ChiswickCReynoldsRMDenisonFet al.Effect of metformin on maternal and fetal outcomes in obese pregnant women (EMPOWaR): A randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol2015; 3: 778–786.
